Table 1 Demographic information and biomarker data
| FTLD subgroups | |||||||
|---|---|---|---|---|---|---|---|
| FTLD-TDP subgroups | |||||||
| FTLD | FTLD-tau | FTLD-TDP | FTLD-C9orf72 | FTLD-GRN | Controls | Alzheimer’s disease | |
| Gender, % male/female (n) |
50/50 (46) |
70/30 (10) |
44/56 (34) |
37/63 (19) |
56/44 (9) |
55/45 (20) |
49/51 (45) |
| Age at LP (years) |
63.6 (55.1–71.7)a |
70.3 (56.2–74.4) |
63.3 (54.5–71.6) |
59.0 (53.7–69.5)* |
67.3 (63.3–71.9) |
69.4 (61.5–74.7) |
71.2 (66.7–79.2) |
| Age at onset (years) |
62.0 (53.8–69.2)a |
56.0 (54.0–71.0) |
63.5 (52.8–69.2) |
56.0 (48.0–67.0) |
66.0 (61.5–70.0) | N/A |
69.5 (64.3–75.8) |
| Age at death (years) |
65.9 (60.2–75.1) |
74.0 (60.8–76.2) |
62.9 (57.5–72.5) |
57.7 (52.3–62.6)*† |
69.1 (61.1–74.2) | N/A | N/A |
| APOE ε4 carriers, % (n) |
32.4 (37) |
57.1 (7) |
27.6 (29) |
30.8 (13) |
20.0 (10) |
33.3 (6) |
59.5 (42) |
| MMSE at LP (0–30), (n) |
21 (15–25) (29) |
23 (22–27) (5) |
19 (14–25) (23) |
15 (7–21) (10)† |
23 (16–26) (7) | N/A |
20 (15–25) (42) |
| Serum progranulin (ng/mL) |
95 (60–126)a,b |
96 (76–167)* |
95 (61–125) |
107 (91–125)* |
48 (39–63) |
130 (101–175) |
119 (98–145) |
| CSF progranulin (ng/mL) |
3.39 (2.29–3.85)a |
3.79 (2.94–4.23)* |
3.00 (2.10–3.64) |
3.21 (2.35–3.74)* |
1.93 (0.97–2.43) |
3.61 (2.92–4.50) |
3.88 (3.22–4.59) |
| CSF Aβ1–42 (pg/mL) |
641 (457–858)a |
543 (438–960) |
698 (481–862) |
695 (457–819) |
708 (578–943) |
812 (646–1108) |
509 (372–594)b |
| CSF t-tau (pg/mL) |
320 (219–420)a |
331 (197–400) |
330 (236–464) |
252 (178–332)* |
379 (296–559) |
257 (173–381) |
627 (429–928)b |
| CSF p-tau181 (pg/mL) |
36.7 (28.3–49.0)a |
35.5 (26.9–58.8) |
37.2 (28.8–49.0) |
33.0 (22.0–49.0) |
36.0 (30.9–42.5) |
40.3 (32.9–58.6) |
80.0 (60.5–105.0)b |
| CSF p-tau181/t-tau ratio |
0.117 (0.097–0.149)b |
0.144 (0.095–0.152)* |
0.116 (0.092–0.145) |
0.142 (0.105–0.164)* |
0.088 (0.076–0.114) |
0.176 (0.156–0.197) |
0.132 (0.104–0.149)b |
| CSF Nf-L (pg/mL) |
3967 (2556–7148)a,b |
2508 (1217–6053)* |
4323 (3367–7358) |
3446 (2611–4049)* |
7323 (5432–9097) |
1136 (547–3984) |
1597 (1281–2781) |
| CSF pNf-H (ng/mL) |
0.43 (0.21–1.25) |
0.54 (0.29–1.45)* |
0.41 (0.16–0.95) |
0.45 (0.22–0.95)* |
0.04 (0.04–0.33) |
0.33 (0.04–1.36) |
0.47 (0.19–1.43) |